Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales - Fan, Li; Li, Yue; Chen, Jia-Yu; Zheng, Yong-Fa; Xu, Xi-Ming (Cancer letters, 2019)
Keywords: Ani-PD-1/L1; Animals; Anti-CTLA-4; Antigens; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Apoptosis; Autoimmune diseases; Biomarkers; Cancer; Cancer immunotherapy; Carcinogenesis; Cell Communication; Clinical trials; Combinational immunotherapy; Editing; Fibroblasts; Homeostasis; Humans; Immune checkpoint; Immune checkpoint modulators; Immunoglobulins; Immunomodulation; Immunosurveillance; Immunotherapy; Ligands; Lymphocytes; Melanoma; Molecular Targeted Therapy; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; PD-1 protein; Proteins; Response rates; Signal Transduction; Treatment Outcome; Tumor Microenvironment; Tumor necrosis factor-TNF; Ani-PD-1/L1; Immune checkpoint modulators; Combinational immunotherapy; Anti-CTLA-4